Mavenir’s Converged Packet Core to power Deutsche Telekom’s 5G standalone (SA) network in Germany
Deutsche Telekom andMavenir announced the successful delivery and deployment of cloud-native 5G Core to Deutsche Telekom in Germany. Deutsche Telekom selected Mavenir as the supplier for software applications to run on its defined hardware and the existing Kubernetes-based platform of its German business, ensuring an open architecture approach. As part of the deployment process, the Converged Packet Core was integrated with Telekom’s existing multi-vendor access network and other system components.
The new Converged Packet Core supports data, voice, and messaging services and network slicing. The initial network slicing use case is focused on live video broadcasting. The deployment has been successfully certified against devices from the major terminal vendors.
The Mavenir solution is based on automated software delivery and network upgrades. This will allow new Converged Packet Core services with all the required network functions to be deployed in minutes by using the automation framework of Deutsche Telekom. It is largely self-updating for the entire lifecycle of each application. The platform can automatically synchronize production environment resources and configuration with changes expressed in code. It is therefore less prone to the human errors that come with manual testing and deployment.
Dr. Abdurazak Mudesir, Group CTO Deutsche Telekom, said: “The deployment of a cloud-native Standalone (SA) core marks a key milestone in the evolution of our 5G architecture. This sets us on a path towards a fully automated network with the reliability, massive scale and flexibility required to deliver innovative 5G SA services to our consumer and enterprise customers.”
Pardeep Kohli, Mavenir’s President and CEO, said, “The Mavenir solution deployed with Deutsche Telekom in Germany, creates the foundation for the future introduction of 5G standalone enabling new applications and services to take advantage of 5G features such as low latency and network slicing.”
Key attributes of Mavenir’s solution include:
- Open Architecture: uses Telekom-defined hardware, a Kubernetes-based platform, and the automation framework of Deutsche Telekom.
- Network slicing support: with dedicated control and user plane network functions for meeting strict service level agreements.
- Cloud-native design: a fully containerized solution based on stateless microservice architecture that allows better resiliency and faster recovery in the event of network failures. It also enables the easy onboarding of users on Telekom’s Containers-as-a-Service (CaaS) that can be run on any public, private or hybrid cloud environment.
- Third-party vendor network function (NF) integration: integrated with multiple third-party vendors, including 4G and 5G access network and subscriber management functions.
- Converged architecture: Supports 4G, 5G non-standalone (NSA), and 5G standalone (SA) modes and enables all access technologies to run on a common cloud-native platform by Deutsche Telekom.
Mavenir’s Converged Packet Core solution is part of its cloud-native MAVcore portfolio built on an open architecture which offers easy scaling of applications and services, hardware decoupling, agility, portability and resilience.
- Case Study YouTube Video: GitOps Based Cloud Native 5GC Lifecycle Management – Based on Mavenir 5GC Implementation in Deutsche Telekom Technik with Das Schiff (T-CaaS @ TDG) Platform - Michal Sewera & Samy Nitsche, Deutsche Telekom
- Solution Brief: Mavenir’s Converged Packet Core Solution
About Deutsche Telekom: https://www.telekom.com/companyprofile
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Mavenir PR Contacts:
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
Deutsche Telekom AG
Tel.: +49 228 181 – 49494
Further information for the media at:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The LYCRA Company Announces Collaboration With Qore ® to Use QIRA ® for Next Generation Bio-derived LYCRA ® Fiber at Scale29.9.2022 02:00:00 CEST | Press release
The LYCRA Company,a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, today announced it has entered into an agreement with Qore® to enable the world’s first large-scale commercial production of bio-derived spandex using QIRA®, the next generation 1,4-butanediol (BDO), as one of its main ingredients. This will result in 70% of the LYCRA® fiber content being derived from annually renewable feedstock. This change could potentially reduce the carbon footprint of LYCRA® fiber by up to 44%* versus equivalent product made from fossil-based resources, while maintaining the same high-quality performance parameters of traditional LYCRA® fiber. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005020/en/ The LYCRA Company signs an agreement with Qore® LLC to enable large-scale production of bio-derived spandex. Pictured – Julien Born, CEO of The LYCRA Company (left), and Jon
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation ™28.9.2022 22:30:00 CEST | Press release
Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the journal of the International Neuromodulation Society, Neuromodulation,further establish the efficacy and safety of ReActiv8 Restorative Neurostimulation, including compelling long-term durability and improvement over time on key outcome measures in the treatment of intractable chronic low back pain. The three-year data show improvements over results from the patients’ one-year and two-year visits on virtually all key efficacy measures. Of note: Outcome measure 1-year result (N = 176) 2-year result (N = 156) 3-year result (N = 133) Patients reporting pain intensity (Visual Analog Scale (VAS) score) reduced by 50% or more from baseline 64% 71% 77% Patients reporting a greater than 20-point reduction in Oswestry Disability Index 57% 61% 63% Patients reporting VAS score < 2.5 52% 65% 67% Patients taking opioids at basel
New Study From Egon Zehnder and Kearney Debunks the Myth of a Workplace Generational Divide28.9.2022 16:00:00 CEST | Press release
Egon Zehnder, the world’s preeminent leadership advisory firm, in partnership with Kearney, a leading global management consulting firm, today released findings from a new survey with over 8,000 respondents from eight different countries dismissing the myth of a generation divide in the workplace and showing that despite what is often believed, Gen Z, Millennials, Gen X and Boomers are more alike than different when it comes to workplace matters. The survey, titled “Different Generations, Same Ideals: What Workers of All Ages Value in their Jobs,” analyzed the similarities and differences among generations and found that they share more commonalities, especially when it comes to personal well-being, work-life balance, and desired traits from leadership. The most notable difference between the generations is how each group defines and plans to achieve their career desires. Key Findings from the survey include: Personal well-being, stability, and work-life balance matter more than money
BYD Announces Pre-sale Prices of European Passenger Car Range28.9.2022 15:35:00 CEST | Press release
BYD announces the pre-sale prices of its new European passenger car range. The world’s leading manufacturer of new energy vehicles and power batteries immediately introduces three full-electric passenger vehicles which will be delivered to Norway, Sweden, Denmark, the Netherlands, Belgium, Luxembourg and Germany. Before the end of the year customers in France and the United Kingdom will also have access to BYD’s zero-emission vehicles. After that, more dealers will be appointed supporting BYD’s plans to cover all major markets in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005587/en/ BYD Europe Product Premiere 2022 The pre-sale price for the BYD ATTO 3 is € 38,000. The BYD HAN and TANG pre-sale prices are € 72,000. These pre-sale prices apply to Germany as a reference for Europe and may differ from country to country. The three full-electric BYD vehicles are technologically advanced and well-suited to the e
Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany28.9.2022 15:27:00 CEST | Press release
Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany. The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy(*) such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services. Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros. (*) Targeted radioligand therapy is an innovative approach to cancer treatment that is considered to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom